Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 6/20 | 0.40 |
| ▸ | CDK8 | P49336 | 6/20 | 0.40 |
| ▸ | FDPS | P14324 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.35 |
| ▸ | PLAU | P00749 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | LPO | P22079 | 1/20 | 0.33 |
| ▸ | PELI1 | Q96FA3 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16532700 | 0.83 | ALDH1A1 (0.40) | FDPSMEN1KMT2APTP4A3HDAC8 | |
| SCHEMBL7171508 | 0.81 | PTP4A3 (0.38) | FDPSMEN1KMT2APTP4A3LPO | |
| SCHEMBL1756847 | 0.81 | TBXAS1 (0.40) | CCNCCDK8FDPSMEN1KMT2A | |
| SCHEMBL7171507 | 0.81 | PTP4A3 (0.38) | FDPSMEN1KMT2APTP4A3LPO | |
| SCHEMBL1756842 | 0.81 | TBXAS1 (0.40) | CCNCCDK8FDPSMEN1KMT2A | |
| SCHEMBL22481929 | 0.80 | PTP4A3 (0.37) | FDPSPTP4A3HDAC8HDAC1 | |
| SCHEMBL2490683 | 0.80 | CA12 (0.41) | FDPSMEN1KMT2APTP4A3CYP1A2 | |
| SCHEMBL2490681 | 0.80 | CA12 (0.41) | FDPSMEN1KMT2APTP4A3CYP1A2 | |
| SCHEMBL16532719 | 0.79 | PTP4A3 (0.37) | FDPSMEN1KMT2AATMPTP4A3 | |
| SCHEMBL19890620 | 0.79 | PTP4A3 (0.37) | CCNCCDK8FDPSMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210163423-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2021-06-03 | — | — | US | disclosed |
| US-10653701-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC. (US) | 2020-05-19 | — | — | US | disclosed |
| US-20190307767-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA, INC. | 2019-10-10 | — | — | US | disclosed |
| EP-3035936-B1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA INC (US) | 2019-03-13 | — | — | EP | disclosed |
| US-9849139-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20170196881-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA, INC. | 2017-07-13 | — | — | US | disclosed |
| US-20170050936-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2017-02-23 | — | — | US | disclosed |
| US-9550770-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20160304471-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2016-10-20 | — | — | US | disclosed |
| US-20150175601-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2015-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190307767-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | DCK, ABL1, MAP4K2 | CCNC 432/4885CDK8 46/4885FDPS 2719/4885 |
| US-20170196881-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | DCK, ABL1, MAP4K2 | CCNC 432/4885CDK8 46/4885FDPS 2719/4885 |
| US-20150175601-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, PIK3CA, PLK1 | CCNC 434/4885CDK8 82/4885FDPS 887/4885 |
| US-20210163423-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, PIK3CA, PLK1 | CCNC 434/4885CDK8 82/4885FDPS 887/4885 |
| US-10653701-B2 | Substituted quinazolines for inhibiting kinase activity | DCK, ABL1, MAP4K2 | CCNC 432/4885CDK8 46/4885FDPS 2719/4885 |
| US-20170050936-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CDK2, MAP3K6, MAP3K2 | CCNC 244/4885CDK8 54/4885FDPS 947/4885 |
| US-20160304471-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, PIK3CA, PLK1 | CCNC 434/4885CDK8 82/4885FDPS 887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.